Welcome to our dedicated page for Polypid news (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on Polypid stock.
PolyPid Ltd. develops locally administered, controlled-release therapeutics based on its proprietary PLEX drug-delivery technology. The company’s lead product candidate, D-PLEX100, is designed for prevention of surgical site infections in abdominal colorectal surgery, and company updates commonly cover Phase 3 SHIELD II data, pharmacokinetics, FDA interactions, New Drug Application activity, and manufacturing-readiness topics.
PolyPid news also includes financial results, operational highlights, investor-conference participation, and broader pipeline references spanning surgical care, oncology, obesity, diabetes, and other metabolic-disease applications. Recurring disclosures focus on clinical and regulatory progress, product-candidate development, and the financing and business updates typical of a late-stage biopharmaceutical issuer.
PolyPid Ltd. (Nasdaq: PYPD) has announced the pricing of its initial public offering (IPO) of 3,750,000 ordinary shares at $16.00 each, aiming to raise gross proceeds of $60 million. The shares are expected to start trading on the Nasdaq Global Market on June 26, 2020, with the offering set to close on June 30, 2020, pending customary conditions. The underwriters have a 30-day option to purchase an additional 562,500 shares at the IPO price. This offering follows the effectiveness of the registration statement by the SEC on June 25, 2020.